rhepgn (Biosynth Carbosynth)
Biosynth Carbosynth is a verified supplier 
Biosynth Carbosynth manufactures this product 
92
Structured Review
Biosynth Carbosynth
rhepgn
Rhepgn, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 92/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rhepgn/EPGN+Human/pm33761358-177-43-44
Average 92 stars, based on 2 article reviews
Rhepgn, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 92/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rhepgn/EPGN+Human/pm33761358-177-43-44
Average 92 stars, based on 2 article reviews
rhepgn - by Bioz Stars,
2026-10
92/100 stars
Images
Related Articles
other:Article Title: EGF-mediated suppression of cell extrusion during mucosal damage attenuates opportunistic fungal invasion. Article Snippet: Chemical inhibitor assays were conducted using the same protocol in the presence or absence of either 5 mM of the EGF receptor inhibitor AG1478 (EMD Millipore Product: 658552) or 50 mM of the MEK inhibitor U0126 (MD Millipore Product: 662005). Recombinant:Article Title: EGF-mediated suppression of cell extrusion during mucosal damage attenuates opportunistic fungal invasion. Article Snippet: .. At the end of the observation period, remaining larvae were humanely euthanized by placing them in ice water for 20 min. Chemical Inhibitors and Recombinant Growth Factors Larvae were treated with either 30 nM rhEGF (Prospec Protein Specialists Product: CYT-217-b) or 250 nM Article Title: EGF-Mediated Suppression of Cell Extrusion During Mucosal Damage Attenuates Opportunistic Fungal Invasion Article Snippet: EGF-mediated suppression of cell extrusion during mucosal damage attenuates opportunistic fungal invasion Sebastian Wurster1, *, Oscar E. Ruiz2, *, Krystin M. Samms2, Alexander M. Tatara3, Nathaniel D. Albert1, Philip H. Kahan2, Anh Trinh Nguyen4,6, Antonios G. Mikos5, Dimitrios P. Kontoyiannis1, #, George T. Eisenhoffer 2, 6, # 1 - Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M.D.. Anderson Cancer Center, Houston, Texas, USA 2 - Department of Genetics, The University of Texas M.D.. Anderson Cancer Center, Houston, Texas, USA 3 - Medical Scientist Training Program, Baylor College of Medicine, Houston, Texas, USA 4 - Department of Microbiology and Molecular Genetics, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA 5 - Department of Bioengineering, Rice University, Houston, TX, USA 6 – Graduate School of Biomedical Sciences, The University of Texas Graduate School of Biomedical Sciences at Houston, The University of Texas MD Anderson Cancer Center * Co-first authors # Co-corresponding authors and Lead Contacts: George T. Eisenhoffer, PhD Department of Genetics, Unit 1010 The University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd. |